Thorsten Ruf
Hoffmann-La Roche
7 Papers
6 Citations
Thorsten Ruf is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Alectinib & Medicine. The author has an hindex of 5, co-authored 7 publications.
Chat about Author
Papers
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Tony Mok,D.R. Camidge,Shirish M. Gadgeel,Rafael Rosell,Rafal Dziadziuszko,Dai Woo Kim,Maurice Pérol,S-H.I. Ou,Joonghyun Ahn,Alice T. Shaw,Walter Bordogna,Vlatka Smoljanovic,Magalie Hilton,Thorsten Ruf,Johannes Noe,Solange Peters +15 more
TL;DR: The publisher regrets that this article has been temporarily removed and a replacement will appear as soon as possible in which the reason for the removal will be specified.
537
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies
Peter N. Morcos,Katrijn Bogman,Stanislas Hubeaux,Carolina Sturm-Pellanda,Thorsten Ruf,Walter Bordogna,Sophie Golding,Ali Zeaiter,Markus Abt,Bogdana Balas +9 more
TL;DR: Alectinib does not prolong the QTc interval or cause changes in cardiac function to a clinically relevant extent, with the exception of a decrease in heart rate which was generally asymptomatic.
35
Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC.
Solange Peters,Tony Mok,Shirish M. Gadgeel,Rafael Rosell,Rafal Dziadziuszko,Dong Wan Kim,Maurice Pérol,Sai-Hong Ignatius Ou,Alice T. Shaw,Walter Bordogna,Vlatka Smoljanovic,Magalie Hilton,Thorsten Ruf,Venice Rosale Archer,D. Ross Camidge +14 more
TL;DR: Final, mature PFS from the global phase III ALEX study of ALC vs CRZ in untreated, advanced/metastatic ALK+ NSCLC in treated patients shows positive results for ALC and CRZ.
24
Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers.
TL;DR: In healthy volunteers, aleglitazar was excreted mainly in the form of inactive metabolites, mostly M1 and M6, with only a small proportion eliminated unchanged, and no serious adverse events were reported.
7
No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
TL;DR: There was a trend for aleglitazar to cause a small dose-dependent decrease in QT interval using a study-specific correction factor for heart rate, and single supratherapeutic doses of aleg litazar are not associated with prolongation of the QT intervals corrected for heart rates.
3